List
The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until April, 2020.
-
Innovative Mitigation of Radiation Effects in Advanced Technology Nodes
SBC: Microelectronics Research Development Corporation Topic: DTRA16A003Micro-RDC has developed portable radiation effects test structures that scale to new process nodes.These structures will enable the investigation of the effects of radiation on the new technology from the material processing level as well as the circuit level.Fabricating the chosen structures and the refinement of software to extract the model parameters will be completed in this effort.A suite of ...
STTR Phase II 2018 Department of DefenseDefense Threat Reduction Agency -
Developing a small peptide to control autoimmune inflammation in type diabetes
SBC: Op-T-Mune, Inc Topic: NIAIDAbstract Type Diabetes T D affects an ever growing population While this disease typically has been associated with juveniles the disease in adult populations is rapidly increasing The defining clinical component is insulin loss which occurs because of sustained inflammation in the islets At present there is no means to prevent or reverse insulin loss A major inflammatory pathway in T D ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines
SBC: VaxNewMO Topic: NIAIDPROJECT SUMMARY Pneumococcal pneumonia remains the leading cause of bacterial pneumonia in both children under years of age and adults over years of age The standard preventative therapy is the conjugate vaccine Prevnar which consists of an immunogenic carrier protein covalently attached to one of thirteen pneumococcal capsular polysaccharides Although Prevnar has significantly red ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
ErythroMer Nanoscale Bio Synthetic Red Cell Substitute
SBC: Kalocyte Inc Topic: NHLBIPROJECT SUMMARY There is need for an artificial oxygen O carrier to substitute for banked blood in settings where stored blood is unavailable pre hospital care transport austere environments undeveloped countries or undesirable transfusion risk exceeds benefit To address this need we developed ErythroMer EM a first in class nano cyte blood substitute EM is a deformable ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
E training of Inmate Peer Caregivers for Enhancing Geriatric and End of life Care in Prisons
SBC: KLEIN BUENDEL, INC Topic: NIAThe US has the highest incarceration rate in the world imprisoning people per The older adult segment of the prison population has more than tripled since and their health issues are common to free people who are years their senior Inmates over the age of have a death rate that is times that of prisoners aged US prison systems are facing sharply increased dema ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Screening for the autoimmune component of multiple sclerosis
SBC: Op-T-Mune, Inc Topic: NIAIDMultiple Sclerosis is an inflammatory neurodegenerative disease with autoimmune components that exacerbate and potentially initiate the disease Diagnosis is invasive time consuming relatively expensive and extremely difficult In fact no clear diagnostic test yet exist A major concern is that MS symptoms are identical to the symptoms of numerous other neurologic diseases OND as well as some ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Non invasive risk assessment tool for pediatric heart failure
SBC: CORAMIR BIOMEDICAL, INC. Topic: NHLBIABSTRACT Heart Failure HF in pediatric patients is a devastating disease that is difficult to evaluate even with invasive hospital procedures Importantly and unique to the pediatric population approximately of pediatric HF patients spontaneously recover normal heart function within year of diagnosis Unfortunately there is no reliable clinical parameter or biomarker that allows pedia ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Novel HDAC Inhibitors for Treatment of Hemoglobinopathies
SBC: CETYA THERAPEUTICS, INC. Topic: NHLBIProject Summary Induction of normal but developmentally silenced fetal globin expression reduces anemia and ameliorates clinical severity in the beta hemoglobinopathies HDACs and are components of the NURD repressor complex which promotes silencing of fetal globin in adult cells Prior generation HDAC inhibitors have increased fetal globin in patients but had limitations for pharmaceu ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Develop a new cisplatin based drug combination with reduced ototoxicity
SBC: GATEWAY BIOTECHNOLOGY, INC. Topic: NIDCDPROJECT SUMMARY In spite of recent new drug developments platinum based drugs such as cisplatin are still widely used to treat solid organ malignancies Besides its limited efficacy serious side effects have been associated with the use of cisplatin such as bilateral and irreversible hearing loss In the cochlea cisplatin can trigger the production of reactive oxygen species and activate sev ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Developing a Nutraceutical Product against Noise Induce Hearing Loss
SBC: GATEWAY BIOTECHNOLOGY, INC. Topic: NIDCDPROJECT SUMMARY The most common occupational and environmental hazard in this country is noise Itandapos s not surprising then that noise induced hearing loss NIHL is the second most common form of sensorineural hearing deficit behind only age related hearing loss presbycusis Although therapeutics that target the free radical pathway have shown promise for reducing NIHL there are no effe ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health